ARTICLE | Company News

J&J offers Olysio cost-sharing in Scotland

October 15, 2014 1:45 AM UTC

The Scottish Medicines Consortium recommended Olysio simeprevir from Medivir AB (SSE:MVIR B) and Johnson & Johnson (NYSE:JNJ) in combination with other therapies to treat chronic HCV genotypes 1 and 4 infection in patients who are treatment-naive or unresponsive to prior therapies.

J&J's Janssen unit also proposed a "Pay If You Clear" reimbursement scheme to NHS Scotland, in which the company would cover Olysio's cost to patients who do not achieve a sustained virologic response (SVR) 12 weeks after treatment. ...